Andrea Fagiolini
Professor of Psychiatry at the University of Siena; Director of Psychiatry at Siena University Hospital
Data updated
Research Footprint
Andrea Fagiolini appears in 8 tracked papers (2022–2026), most studied alongside Ketamine, Esketamine and Placebo, across Depressive Disorders, Anxiety Disorders and Bipolar Disorder.
Most-cited paper: Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and efficacy (REAL-ESK study) (127 citations).
Frequent co-authors: David Erritzoe, Claudio Agnorelli and David Nutt.
Background & Research
Andrea Fagiolini is an Italian psychiatrist and academic based at the University of Siena. Public university and journal pages identify him as a professor in the Department of Molecular and Developmental Medicine and director of the Psychiatry postgraduate school/psychiatry unit in Siena. His research interests include mood disorders, psychopharmacology, suicidality, and treatment-resistant psychiatric illness, which aligns with the ketamine/esketamine and neuroplasticity papers in your database.
Key Impact
He is a major clinical psychiatry researcher with work spanning depression, bipolar disorder, ketamine/esketamine, and broader neuropsychiatric treatment innovation.
Collaboration Network
12 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Andrea Fagiolini is associated with.